STL Index for: Roflumilast

Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™).

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Explore two case studies of plaque psoriasis, treatment challenges, and novel therapeutic options, including topical roflumilast 0.3% cream. Learn how targeting PDE4 can improve psoriasis management, offering a non-steroidal, effective, and convenient solution for patients with different severities.

Update on Roflumilast foam, 0.3% (Zoryve®), Birch triterpenes gel (Filsuvez®), Rapamycin anhydrous gel, 3.9% (Qtorin™), Bimekizumab-bkzx for SC use (Bimzelx®), Secukinumab for SC use (Cosentyx®), and Ustekinumab-auub for SC/IV use (Wezlana™).

Targeting PDE4 with the selective inhibitor roflumilast, specifically through topical cream at a concentration of 0.3%, has proven to be an effective and well-tolerated strategy for treating plaque psoriasis.

Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...

Update covering: Roflumilast cream 0.3% (Zoryve™), Ruxolitinib cream 1.5% (Opzelura™), HA-based dermal filler (Juvéderm® Volux™ XC), Abrocitinib tablets (Cinbinqo®), LetibotulinumtoxinA for injection (Letybo®), Berotralstat capsules (Orladeyo®), Mogamulizumab IV infusion (Poteligeo®), and Avacopan capsules (Tavneos®).